Suchergebnisse - "Conte, Pierfranco"

PubPharm (382)

1

Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer

enthalten in: Journal of the National Cancer Institute | 2024

von Dieci, M. | Conte, P. | Bisagni, G. | +15

2

Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer : 10-Year Update of the ShortHER Phase III Randomized Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Conte, P. | Bisagni, G. | Piacentini, F. | +18

3

Tucatinib's journey from clinical development to clinical practice : New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread

enthalten in: Cancer treatment reviews | 2023

von Criscitiello, C. | Corti, C. | De Laurentiis, M. | +17

4

Examining technology-assisted rehabilitation for older adults' functional mobility : a network meta-analysis on efficacy and acceptability

enthalten in: NPJ digital medicine | 2023

von Cieślik, B. | Mazurek, J. | Wrzeciono, A. | +4

5

Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer : Subgroup analyses from the phase III OlympiAD trial

enthalten in: International journal of cancer | 2023

von Senkus, E. | Delaloge, S. | Domchek, S. | +8

6

Pathologic complete response and individual patient prognosis after neoadjuvant chemotherapy plus anti-human epidermal growth factor receptor 2 therapy of human epidermal gowth factor receptor 2-positive early breast cancer

enthalten in: Journal of clinical oncology | June 01, 2023

von Mackelenbergh, M. | Loibl, S. | Untch, M. | +26

7

Re-evaluation of pathologic complete response as a surrogate for event-free and overall survival in human epidermal growth factor receptor 2-positive, early breast cancer treated with neoadjuvant therapy including anti-human epidermal growth factor receptor 2 therapy

enthalten in: Journal of clinical oncology | June 01, 2023

von Squifflet, P. | Saad, E. | Loibl, S. | +26

8

Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Squifflet, P. | Saad, E. | Loibl, S. | +27

ErratumIn: J Clin Oncol. 2023 Dec 19;:JCO2302620. - PMID 38113406

9

Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von van Mackelenbergh, M. | Loibl, S. | Untch, M. | +27

10

OlympiAD extended follow-up for overall survival and safety : Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

enthalten in: European journal of cancer (Oxford, England : 1990) | 2023

von Robson, M. | Im, S. | Senkus, E. | +10

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[39]